Objectives

After participating in this educational activity, attendees should be able to:
1| Review the Pathophysiology of Pulmonary Hypertension in Interstitial Lung Disease (PH-ILD).
2| Review Current and Emerging Therapeutic Options for PH-ILD.
3| Analyze Diagnostic Criteria and Clinical Trial Design considerations.
4| Develop a Multimodality Management Approach for PH-ILD.

 

Presenter(s): 

Talal Dahhan, MD, MMEL, MHA, cLM, cHCM, cHQA, FACP, FCCP
Associate Professor of Medicine, UMass Chan Medical School-Baystate
Adjunct Associate Professor of Medicine, Duke University School of Medicine
Medical Director, Pulmonary Vascular Diseases Program
Chief, Division of Pulmonary and Critical Care, Department of Medicine, Baystate Health
 

 

NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?
Talal Dahhan, MD, MMEL, MHA, cLM, cHCM, cHQA, FACP, FCCPSpeakerNo relevant relationships with ineligible companies to discloseNo
Session date: 
01/29/2025 - 8:00am to 9:00am EST
Location: 
Baystate Medical Center
759 Chestnut Street
Chestnut Conference Room 1A & B & Webinar
Springfield, MA 01199
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category 1 CME credit
    Baystate Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PA’s should only claim credit commensurate with the extent of their participation.
  • 1.00 ACPE Contact Hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 IPCE Credit Hour(s)

Please login or register to take this course.